Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine [seecomments]. Fromm MF, Kim RB, Stein CM, Wilkinson GR, Roden DM (1999) Circulation 99: 552-7 The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. Kim RB, Fromm MF, Wandel C, Leake B, Wood AJ, Roden DM, Wilkinson GR (1998) J Clin Invest 101: 289-94 DeltaNp73alpha regulates MDR1 expression by inhibiting p53 function. Vilgelm A, Wei JX, Piazuelo MB, Washington MK, Prassolov V, El-Rifai W, Zaika A (2008) Oncogene 27: 2170-6 Predicting clopidogrel response using DNA samples linked to an electronic health record. Delaney JT, Ramirez AH, Bowton E, Pulley JM, Basford MA, Schildcrout JS, Shi Y, Zink R, Oetjens M, Xu H, Cleator JH, Jahangir E, Ritchie MD, Masys DR, Roden DM, Crawford DC, Denny JC (2012) Clin Pharmacol Ther 91: 257-63 Identification of functionally variant MDR1 alleles among European Americans and African Americans. Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, Taylor A, Xie HG, McKinsey J, Zhou S, Lan LB, Schuetz JD, Schuetz EG, Wilkinson GR (2001) Clin Pharmacol Ther 70: 189-99 Transporters and drug therapy: implications for drug disposition and disease. Ho RH, Kim RB (2005) Clin Pharmacol Ther 78: 260-77 "Inactive" excipients such as Cremophor can affect in vivo drug disposition. Wandel C, Kim RB, Stein CM (2003) Clin Pharmacol Ther 73: 394-6 Effects of nelfinavir and its M8 metabolite on lymphocyte P-glycoprotein activity during antiretroviral therapy. Donahue JP, Dowdy D, Ratnam KK, Hulgan T, Price J, Unutmaz D, Nicotera J, Raffanti S, Becker M, Haas DW (2003) Clin Pharmacol Ther 73: 78-86 Intestinal drug transporter expression and the impact of grapefruit juice in humans. Glaeser H, Bailey DG, Dresser GK, Gregor JC, Schwarz UI, McGrath JS, Jolicoeur E, Lee W, Leake BF, Tirona RG, Kim RB (2007) Clin Pharmacol Ther 81: 362-70 Digoxin toxicity and ritonavir: a drug interaction mediated through p-glycoprotein? Phillips EJ, Rachlis AR, Ito S (2003) AIDS 17: 1577-8 Impact of African herbal medicines on antiretroviral metabolism. Mills E, Foster BC, van Heeswijk R, Phillips E, Wilson K, Leonard B, Kosuge K, Kanfer I (2005) AIDS 19: 95-7 Role of the multidrug resistance protein-1 in hypertension and vascular dysfunction caused by angiotensin II. Widder JD, Guzik TJ, Mueller CF, Clempus RE, Schmidt HH, Dikalov SI, Griendling KK, Jones DP, Harrison DG (2007) Arterioscler Thromb Vasc Biol 27: 762-8 Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study. Haas DW, Smeaton LM, Shafer RW, Robbins GK, Morse GD, Labbe L, Wilkinson GR, Clifford DB, D'Aquila RT, De Gruttola V, Pollard RB, Merigan TC, Hirsch MS, George AL, Donahue JP, Kim RB (2005) J Infect Dis 192: 1931-42 Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study. Ribaudo HJ, Liu H, Schwab M, Schaeffeler E, Eichelbaum M, Motsinger-Reif AA, Ritchie MD, Zanger UM, Acosta EP, Morse GD, Gulick RM, Robbins GK, Clifford D, Haas DW (2010) J Infect Dis 202: 717-22 The serotonin transporter (SLC6A4) is present in B-cell clones of diverse malignant origin: probing a potential anti-tumor target for psychotropics. Meredith EJ, Holder MJ, Chamba A, Challa A, Drake-Lee A, Bunce CM, Drayson MT, Pilkington G, Blakely RD, Dyer MJ, Barnes NM, Gordon J (2005) FASEB J 19: 1187-9 Contribution of hepatic organic anion-transporting polypeptides to docetaxel uptake and clearance. Lee HH, Leake BF, Teft W, Tirona RG, Kim RB, Ho RH (2015) Mol Cancer Ther 14: 994-1003 The MYND motif is required for repression of basal transcription from the multidrug resistance 1 promoter by the t(8;21) fusion protein. Lutterbach B, Sun D, Schuetz J, Hiebert SW (1998) Mol Cell Biol 18: 3604-11 Influence of the G2677T/C3435T haplotype of MDR1 on P-glycoprotein trafficking and ibutilide-induced block of HERG. McBride BF, Yang T, Roden DM (2009) Pharmacogenomics J 9: 194-201 Modulation of drug block of the cardiac potassium channel KCNA5 by the drug transporters OCTN1 and MDR1. Yang T, McBride BF, Leake BF, Kim RB, Roden DM (2010) Br J Pharmacol 161: 1023-33 Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, Roden MM, Belas F, Chaudhary AK, Roden DM, Wood AJ, Wilkinson GR (1999) Pharm Res 16: 408-14 Implications of T-cell P-glycoprotein activity during HIV-1 infection and its therapy. Hulgan T, Donahue JP, Hawkins C, Unutmaz D, D'Aquila RT, Raffanti S, Nicotera F, Rebeiro P, Erdem H, Rueff M, Haas DW (2003) J Acquir Immune Defic Syndr 34: 119-26 MDR1 gene polymorphisms and phase 1 viral decay during HIV-1 infection: an adult AIDS Clinical Trials Group study. Haas DW, Wu H, Li H, Bosch RJ, Lederman MM, Kuritzkes D, Landay A, Connick E, Benson C, Wilkinson GR, Kessler H, Kim RB (2003) J Acquir Immune Defic Syndr 34: 295-8 On the origin of large flexibility of P-glycoprotein in the inward-facing state. Wen PC, Verhalen B, Wilkens S, Mchaourab HS, Tajkhorshid E (2013) J Biol Chem 288: 19211-20 7-Ketocholesterol induces P-glycoprotein through PI3K/mTOR signaling in hepatoma cells. Wang SF, Chou YC, Mazumder N, Kao FJ, Nagy LD, Guengerich FP, Huang C, Lee HC, Lai PS, Ueng YF (2013) Biochem Pharmacol 86: 548-60 Application of three-dimensional quantitative structure-activity relationships of P-glycoprotein inhibitors and substrates. Ekins S, Kim RB, Leake BF, Dantzig AH, Schuetz EG, Lan LB, Yasuda K, Shepard RL, Winter MA, Schuetz JD, Wikel JH, Wrighton SA (2002) Mol Pharmacol 61: 974-81 Contribution of Organic Anion-Transporting Polypeptides 1A/1B to Doxorubicin Uptake and Clearance. Lee HH, Leake BF, Kim RB, Ho RH (2017) Mol Pharmacol 91: 14-24 Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein. Ekins S, Kim RB, Leake BF, Dantzig AH, Schuetz EG, Lan LB, Yasuda K, Shepard RL, Winter MA, Schuetz JD, Wikel JH, Wrighton SA (2002) Mol Pharmacol 61: 964-73 Identification and characterization of a new tubulin-binding tetrasubstituted brominated pyrrole. Mooberry SL, Weiderhold KN, Dakshanamurthy S, Hamel E, Banner EJ, Kharlamova A, Hempel J, Gupton JT, Brown ML (2007) Mol Pharmacol 72: 132-40 A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models. Kinney GG, O'Brien JA, Lemaire W, Burno M, Bickel DJ, Clements MK, Chen TB, Wisnoski DD, Lindsley CW, Tiller PR, Smith S, Jacobson MA, Sur C, Duggan ME, Pettibone DJ, Conn PJ, Williams DL (2005) J Pharmacol Exp Ther 313: 199-206 Genetic and non-genetic determinants of raltegravir penetration into cerebrospinal fluid: a single arm pharmacokinetic study. Johnson DH, Sutherland D, Acosta EP, Erdem H, Richardson D, Haas DW (2013) PLoS One 8: e82672 Role of the MDR-1-encoded multiple drug resistance phenotype in prostate cancer cell lines. Theyer G, Schirmböck M, Thalhammer T, Sherwood ER, Baumgartner G, Hamilton G (1993) J Urol 150: 1544-7 The use of a DNA biobank linked to electronic medical records to characterize pharmacogenomic predictors of tacrolimus dose requirement in kidney transplant recipients. Birdwell KA, Grady B, Choi L, Xu H, Bian A, Denny JC, Jiang M, Vranic G, Basford M, Cowan JD, Richardson DM, Robinson MP, Ikizler TA, Ritchie MD, Stein CM, Haas DW (2012) Pharmacogenet Genomics 22: 32-42 Mibefradil is a P-glycoprotein substrate and a potent inhibitor of both P-glycoprotein and CYP3A in vitro. Wandel C, Kim RB, Guengerich FP, Wood AJ (2000) Drug Metab Dispos 28: 895-8 OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB (1999) Drug Metab Dispos 27: 866-71 Hepatic uptake of the novel antifungal agent caspofungin. Sandhu P, Lee W, Xu X, Leake BF, Yamazaki M, Stone JA, Lin JH, Pearson PG, Kim RB (2005) Drug Metab Dispos 33: 676-82 Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Choo EF, Leake B, Wandel C, Imamura H, Wood AJ, Wilkinson GR, Kim RB (2000) Drug Metab Dispos 28: 655-60 Estrogen and insulin transport through the blood-brain barrier. May AA, Bedel ND, Shen L, Woods SC, Liu M (2016) Physiol Behav 163: 312-321 Oral cyclosporin A inhibits CD4 T cell P-glycoprotein activity in HIV-infected adults initiating treatment with nucleoside reverse transcriptase inhibitors. Hulgan T, Donahue JP, Smeaton L, Pu M, Wang H, Lederman MM, Smith K, Valdez H, Pilcher C, Haas DW, AIDS Clinical Trials Group Study A5138 Team (2009) Eur J Clin Pharmacol 65: 1081-8 Development and characterization of LLC-PK1 cells containing Sprague-Dawley rat Abcb1a (Mdr1a): comparison of rat P-glycoprotein transport to human and mouse. Booth-Genthe CL, Louie SW, Carlini EJ, Li B, Leake BF, Eisenhandler R, Hochman JH, Mei Q, Kim RB, Rushmore TH, Yamazaki M (2006) J Pharmacol Toxicol Methods 54: 78-89
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.